Atlas Capital Advisors’s Viridian Therapeutics VRDN Stock Holding History

Atlas Capital Advisors’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-859	Closed	-$9.42K	–	677
2019 Q3	$9.42K	Hold	859	–	–	﹤0.01%	576
2019 Q2	$26.4K	Hold	859	–	–	0.01%	535
2019 Q1	$36K	Hold	859	–	–	0.01%	442
2018 Q4	$39.1K	Hold	859	–	–	0.02%	433
2018 Q3	$70.8K	Hold	859	–	–	0.02%	395
2018 Q2	$92.3K	Buy	+859	New	+$90.8K	0.03%	348

Other funds holding VRDN

AVA

Atlas Venture Advisors Boston, Massachusetts $122M AUM 26.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Atlas Capital Advisors's VRDN Position: Q4 2019 in Review

Atlas Capital Advisors sold out of Viridian Therapeutics (VRDN) in Q4 2019, closing a stake of 859 shares — an estimated $9.42K sold.

Atlas Capital Advisors first reported a position in VRDN in Q2 2018 and held it in 6 quarters. The position peaked at $92.3K in Q2 2018. 23 funds tracked by Wall St. Rank hold VRDN as of Q4 2019.

Atlas Capital Advisors reported no remaining Viridian Therapeutics position as of Q4 2019 after selling out during the quarter.
Atlas Capital Advisors sold 859 Viridian Therapeutics shares in Q4 2019, an estimated $9.42K.
Atlas Capital Advisors first reported a position in Viridian Therapeutics in Q2 2018 and held it in 6 quarters.
Atlas Capital Advisors's Viridian Therapeutics position peaked at $92.3K in Q2 2018.
23 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q4 2019.

Based on Atlas Capital Advisors's 13F filing for Q4 2019, filed 28 Jan 2020.